Search by CAS No , Chemical Name or Molecular Formula
"Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent formation of blood clots. It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).",""
Prasugrel Active metabolite
"European Public Assessment Report for Efient" (PDF). EMA. 2009; Koshy S (2012).
We normally respond within 8 hours.
This page contains information about Prasugrel Metabolite M3 (NEM Derivatized) Cas # NA and its Metabolites.
Prasugrel Metabolite M3 (NEM Derivatized) Prasugrel Metabolite M3 (NEM Derivatized) Worldwide Suppliers of Prasugrel Metabolite M3 (NEM Derivatized) https://www.clearsynth.com/en/CSO11181.html Metabolites Clearsynth NA
Product rating: 9 Prasugrel Metabolite M3 (NEM Derivatized) based on 20 ratings
Keywords: Metabolites CS-O-11181 Prasugrel Metabolite M3 (NEM Derivatized) Prasugrel NA 460.56 C24H29FN2O4S
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945